Minerva Neurosciences, Inc. (NERV)
US — Healthcare Sector
Automate Your Wheel Strategy on NERV
With Tiblio's Option Bot, you can configure your own wheel strategy including NERV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NERV
- Rev/Share 0.0056
- Book/Share -3.3945
- PB -0.4831
- Debt/Equity 0.0
- CurrentRatio 7.8499
- ROIC -0.6369
- MktCap 11469192.0
- FreeCF/Share -1900359.9252
- PFCF -0.0
- PE 8.627
- Debt/Assets 0.0
- DivYield 0
- ROE -0.0
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 3
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates
NERV
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
BURLINGTON, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth quarter and year ended December 31, 2024.
Read More
About Minerva Neurosciences, Inc. (NERV)
- IPO Date 2014-07-01
- Website https://www.minervaneurosciences.com
- Industry Biotechnology
- CEO Remy Luthringer
- Employees 8
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.